Screener
Intellia Therapeutics NTLA Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income, net: | ||||
| Interest income | 5,797 | 7,402 | 11,002 | 16,005 |
| Change in fair value of investments, net | 329 | 1,339 | (575) | (786) |
| Total other income, net | 6,126 | 8,741 | 10,427 | 15,219 |
| Net loss | $(106,634) | $(101,255) | $(202,865) | $(215,584) |
| Net loss per share, basic and diluted | $(0.80) | $(0.98) | $(1.61) | $(2.08) |
| Weighted average shares outstanding, basic and diluted | 133,480 | 103,732 | 126,057 | 103,617 |
| Other comprehensive loss: |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's other income, net (note 6)?
- Intellia Therapeutics (NTLA) reported other income, net (note 6) of $6.13M in Q2 2026.
- How has Intellia Therapeutics's other income, net (note 6) changed year-over-year?
- Intellia Therapeutics's other income, net (note 6) decreased by 29.9% year-over-year, from $8.74M to $6.13M.
- What is the long-term trend for Intellia Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Intellia Therapeutics's other income, net (note 6) has grown at a 409.5% compound annual growth rate (CAGR), from -$42K to $28.3M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Intellia Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude